Dupilumab-resistant facial erythema - Dermoscopic, histological and clinical findings of three patients
Open Access
- 1 January 2021
- journal article
- letter
- Published by Elsevier BV in Allergology International
- Vol. 70 (1), 156-158
- https://doi.org/10.1016/j.alit.2020.07.001
Abstract
No abstract availableFunding Information
- Sanofi
- Regeneron
- Sanofi
This publication has 7 references indexed in Scilit:
- The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart reviewJournal of the American Academy of Dermatology, 2020
- Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case seriesBritish Journal of Dermatology, 2019
- Dupilumab facial redness: Positive effect of itraconazoleJAAD Case Reports, 2019
- Characterizing dupilumab facial redness: A multi-institution retrospective medical record reviewJournal of the American Academy of Dermatology, 2019
- Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trialsBritish Journal of Dermatology, 2019
- The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapyJAAD Case Reports, 2018
- Head and neck dermatitis: the role ofMalassezia furfur, topical steroid use and environmental factors in its causationClinical and Experimental Dermatology, 1999